Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform

Lantern Pharma Inc.

Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.
Unregistered warrants have exercise price $2.27, exercisable after 6 months, expire 5 years from initial exercise.
Up to additional $4.85M gross proceeds if warrants fully exercised; no assurance of exercise.
Company plans to separate AI platform withZeta.ai into independent entity; may become publicly listed.
Suspended ATM sales under July 2025 agreement with ThinkEquity; agreement remains in effect.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lantern Pharma Inc. entered into Purchase Agreement with institutional investors valued at approximately $4.4 million (effective 2026-05-12).

Action: entry
Agreement: equity purchase
Counterparty: institutional investors
Value: approximately $4.4 million
Effective: 2026-05-12

Exact text from the filing

On May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors

View on SEC.gov

Browse all material agreements →

Lantern Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.